Syphilis Patents (Class 514/933)
-
Patent number: 8841286Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.Type: GrantFiled: September 26, 2011Date of Patent: September 23, 2014Assignee: Gilead Sciences, Inc.Inventor: Alan Bruce Montgomery
-
Patent number: 7214364Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.Type: GrantFiled: July 3, 2003Date of Patent: May 8, 2007Assignee: Corus Pharma, Inc.Inventor: Alan Bruce Montgomery
-
Patent number: 7087249Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.Type: GrantFiled: April 23, 2002Date of Patent: August 8, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
-
Patent number: 6730329Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.Type: GrantFiled: February 26, 2002Date of Patent: May 4, 2004Inventor: Jeffrey B. Smith
-
Patent number: 6709681Abstract: The present invention provides a dosage form for the treatment of bacterial, viral or fungal conditions which comprises, a pharmaceutically acceptable acidifying agent in an amount sufficient to reduce the pH at an environment of use to below pH4, and a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor; wherein said acidifying agent and said source of nitrite ions or nitrate precursor are separately disposed in respective pharmaceutically acceptable carriers for admixture at the intended environment of use to release NO or NO2 ions. The invention also provides delivery systems for the topical medicament.Type: GrantFiled: June 11, 1999Date of Patent: March 23, 2004Assignee: Aberdeen UniversityInventors: Nigel Benjamin, Hamish Dougall, Anthony Ormerod
-
Patent number: 6159174Abstract: In order to prevent conception and/or the spread of sexually transmitted diseases (STD's) one or more lectins capable of binding sperm and/or the pathogenic microorganisms responsible for STD's are administered to the vagina prior to sexual intercourse. The lectins immobilize the sperm to render them incapable of fertilization and also bind to the microorganisms to render them non-pathogenic or to the cells to prevent infection by the microorganisms. Lectins can also be administered to treat sexually transmitted vaginal infections. The invention also encompasses a device for to be placed in the vault of the vagina which comprises a ring which surrounds the cervix and a membrane spanning the central aperture of the ring to prevent the direct contact of ejaculate with the cervical tissues. The device is impregnated or coated with lectins and releases them into the vaginal environment over a period of time.Type: GrantFiled: November 24, 1998Date of Patent: December 12, 2000Assignee: Legere Pharmaceuticals, Ltd.Inventors: Michael J. Oldham, Bruce F. Rose, Howard C. Krivan
-
Patent number: 6020005Abstract: A genital wart treatment for treating and removing genital warts. The genital wart treatment includes the acts of dissolving a volume of particulate potassium permanganate in a volume of water to form a treatment solution, and repeatedly performing over a duration of time a treatment application comprising the acts of applying the treatment solution on to genital warts and surrounding skin of a subject to wet the genital warts and surrounding skin with the treatment solution, applying a styptic to the wet genital warts and surrounding skin, and then removing an outermost layer of skin on the genital warts.Type: GrantFiled: April 8, 1999Date of Patent: February 1, 2000Inventor: Ervin G. Weathers
-
Patent number: 5840771Abstract: In order to prevent conception and/or the spread of sexually transmitted diseases (STD's) one or more lectins capable of binding sperm and/or the pathogenic microorganisms responsible for STD's are administered to the vagina prior to sexual intercourse. The lectins immobilize the sperm to render them incapable of fertilization and also bind to the microorganisms to render them non-pathogenic or to the cells to prevent infection by the microorganisms. Lectins can also be administered to treat sexually transmitted vaginal infections. The invention also encompasses a device for to be placed in the vault of the vagina which comprises a ring which surrounds the cervix and a membrane spanning the central aperture of the ring to prevent the direct contact of ejaculate with the cervical tissues. The device is impregnated or coated with lectins and releases them into the vaginal environment over a period of time.Type: GrantFiled: September 26, 1997Date of Patent: November 24, 1998Assignee: Legere Pharmaceuticals, Ltd.Inventors: Michael J. Oldham, Bruce F. Rose
-
Patent number: 5814319Abstract: An anti-viral, anti-bacterial, and anti-cancer agent comprising as the effective component, an alkali extraction of Aspalathus linearis which is preferably obtained after extraction by hot water. The agent serves to treat and prevent bacterial infections; to treat and prevent cancer; and to treat or prevent viral infection, for example, infection caused by retroviruses, such as human T-cell leukemia and the AIDS virus. The agent has no side effects.Type: GrantFiled: March 22, 1996Date of Patent: September 29, 1998Assignee: Mitsui Norin Co., Ltd.Inventor: Masatoshi Nakano
-
Patent number: 5698532Abstract: This invention is directed to the novel pyrimidine derivative 1-?5-?2(S)-(2,4-dichloro-5-methoxyphenoxy) propionamido!-2,5-dideoxy-2-fluoro-.beta.-D-arabinofuranosly!-5-ethyluraci l and its use as an antiviral agent, as well as to intermediates useful in the synthesis of this compound.Type: GrantFiled: July 10, 1996Date of Patent: December 16, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Joseph Armstrong Martin, Gareth John Thomas
-
Patent number: 5667817Abstract: Methods for preventing and treating microbial infections in the mammalian female lower genital tract such as vulvitis, vaginitis, cervicitis, and endometritis involve the intra-vaginal and/or intra-uterine infusion of a solution containing a pharmacologically acceptable carrier and chlorine dioxide in an amount ranging from about 5 ppm to 1000 ppm, and having a chlorine dioxide to chlorite ratio of at least 5:1. Typical solutions exhibit a pH compatible with the lower genital tract, e.g., a pH from about 5 to about 7.5. In many embodiments, chlorine dioxide in the solution is produced by reacting a chlorite with a mineral acid and adjusting the pH, by reacting a chlorite with an organic acid having a pK of about 2.8 to 4.2, or by reacting a chlorite at a pH below about 5.5 with a heat-activated saccharide in the presence of an organic acid having a pK of about 2.8 to about 4.2. Sodium chlorite is employed in preferred embodiments.Type: GrantFiled: August 28, 1996Date of Patent: September 16, 1997Assignee: Alcide CorporationInventor: Robert D. Kross
-
Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
Patent number: 5466680Abstract: The present invention relates to a method for enhancing white blood cell functioning and metabolism on a mucosal surface of a mammal. The present invention also relates to a method for treating or preventing a condition in a mammal caused by the presence of a disease-causing agent on a mucosal surface or a cutaneous surface wherein the disease-causing agent can be diminished by the actions of the white blood cells. The present invention yet also relates to a method for healing a wound of a mucosal or cutaneous surface. The present invention also relates to compositions for use in such methods.Type: GrantFiled: March 26, 1992Date of Patent: November 14, 1995Assignee: Cytologics, Inc.Inventor: Michael A. Rudy -
Patent number: 5380529Abstract: The pharmaceutical, vaginal applicable preparation is characterized in that it contains, homogeneously sub-divided, at least one in water soluble poly-vinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexually transmissible or transmitted, respectively, diseases, and/or for vaginal infections, and occasionally one or more auxiliary agent(s), and in that it is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm, especially from 0.06 to 0.2 mm, preferably from 0.07 to 0.15 mm.Type: GrantFiled: August 23, 1993Date of Patent: January 10, 1995Assignee: Laboratoire Lucchini S.A.Inventors: Jean Heusser, Michel Martin